These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 27206893)
1. Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy. Iodice R; Carotenuto A; Dubbioso R; Cerillo I; Santoro L; Manganelli F J Neurol Sci; 2016 Jun; 365():143-6. PubMed ID: 27206893 [TBL] [Abstract][Full Text] [Related]
2. Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Kallmann BA; Fackelmann S; Toyka KV; Rieckmann P; Reiners K Mult Scler; 2006 Feb; 12(1):58-65. PubMed ID: 16459720 [TBL] [Abstract][Full Text] [Related]
3. Prediction of long-term disability in multiple sclerosis. Schlaeger R; D'Souza M; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P Mult Scler; 2012 Jan; 18(1):31-8. PubMed ID: 21868486 [TBL] [Abstract][Full Text] [Related]
4. Visual and motor evoked potentials in the course of multiple sclerosis. Fuhr P; Borggrefe-Chappuis A; Schindler C; Kappos L Brain; 2001 Nov; 124(Pt 11):2162-8. PubMed ID: 11673318 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919 [TBL] [Abstract][Full Text] [Related]
6. The EP-score to assess treatment efficacy in RRMS patients: a preliminary study. Margaritella N; Mendozzi L; Garegnani M; Nemni R; Gilardi E; Pugnetti L Int J Neurosci; 2015 Jan; 125(1):38-42. PubMed ID: 24628579 [TBL] [Abstract][Full Text] [Related]
7. The utility of multimodal evoked potentials in multiple sclerosis prognostication. Ramanathan S; Lenton K; Burke T; Gomes L; Storchenegger K; Yiannikas C; Vucic S J Clin Neurosci; 2013 Nov; 20(11):1576-81. PubMed ID: 23827173 [TBL] [Abstract][Full Text] [Related]
8. Evoked potentials and disability in multiple sclerosis: A different perspective to a neglected method. Kiylioglu N; Parlaz AU; Akyildiz UO; Tataroglu C Clin Neurol Neurosurg; 2015 Jun; 133():11-7. PubMed ID: 25819634 [TBL] [Abstract][Full Text] [Related]
9. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095 [TBL] [Abstract][Full Text] [Related]
10. Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval? Schlaeger R; D'Souza M; Schindler C; Grize L; Kappos L; Fuhr P Clin Neurophysiol; 2014 Sep; 125(9):1889-92. PubMed ID: 24555924 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice]. Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440 [TBL] [Abstract][Full Text] [Related]
12. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806 [TBL] [Abstract][Full Text] [Related]
13. Motor evoked potentials and disability in secondary progressive multiple sclerosis. Facchetti D; Mai R; Micheli A; Marcianó N; Capra R; Gasparotti R; Poloni M Can J Neurol Sci; 1997 Nov; 24(4):332-7. PubMed ID: 9398981 [TBL] [Abstract][Full Text] [Related]
14. Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years. Schlaeger R; Schindler C; Grize L; Dellas S; Radue EW; Kappos L; Fuhr P Mult Scler; 2014 Sep; 20(10):1348-54. PubMed ID: 24574192 [TBL] [Abstract][Full Text] [Related]
15. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis. Giffroy X; Maes N; Albert A; Maquet P; Crielaard JM; Dive D BMC Neurol; 2016 Jun; 16():83. PubMed ID: 27245221 [TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. Invernizzi P; Bertolasi L; Bianchi MR; Turatti M; Gajofatto A; Benedetti MD J Neurol; 2011 Nov; 258(11):1933-9. PubMed ID: 21479648 [TBL] [Abstract][Full Text] [Related]